Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Australian Clinical LabsASX:ACL -0.83%56 EV-to-EBIT is 16.37 as of Aug. 01, 2026, which is 14% above its 10-year median of 14.38. GuruFocus rates ASX:ACL with a GF Score™ of 56/100 and a GF Value™ of A$3.06 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 105 Medical Diagnostics & Research companies, Australian Clinical Labs ranks better than 65.71% on this metric.
The historical rank and industry rank for Australian Clinical Labs's EV-to-EBIT or its related term are showing as below:
ASX:ACL'
s EV-to-EBIT Range Over the Past 10 Years
Min: 3.2 Med: 14.38 Max: 25.01
Current: 16.38
During the past 6 years, the highest EV-to-EBIT of Australian Clinical Labs was 25.01. The lowest was 3.20. And the median was 14.38.
ASX:ACL's EV-to-EBIT is ranked better than 65.71% of 105
companies
in the Medical Diagnostics & Research industry
Industry Median: 23.47
vs ASX:ACL: 16.38
Australian Clinical Labs (ASX:ACL) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Australian Clinical Labs's Enterprise Value for the quarter that ended in Dec. 2025 was A$821.1 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Australian Clinical Labs's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was A$45.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Australian Clinical Labs EV-to-EBIT Related Terms
Australian Clinical Labs EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Australian Clinical Labs's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Australian Clinical Labs EV-to-EBIT vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Australian Clinical Labs's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Australian Clinical Labs's EV-to-EBIT falls into.
Australian Clinical Labs's current Enterprise Value is A$736.4 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Australian Clinical Labs's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was A$45.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Australian Clinical Labs (ASX:ACL) has a EV-to-EBIT of 16.37 as of Aug. 01, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Australian Clinical Labs and its competitors. This is 14% above median its historical median of 14.38. Over the past decade, Australian Clinical Labs' EV-to-EBIT has ranged from 3.20 to 25.01. According to the industry distribution chart, Australian Clinical Labs ranks #36 out of 105 companies in the Medical Diagnostics & Research industry, placing it in the top 34.3%.
Is Australian Clinical Labs' EV-to-EBIT too high?
Australian Clinical Labs' current EV-to-EBIT of 16.37 is 14% above median its 10-year median of 14.38. Over the past 10 years, this metric has ranged from a low of 3.20 to a high of 25.01. The Medical Diagnostics & Research industry median EV-to-EBIT is 23.47. Australian Clinical Labs' value of 16.37 is 30.3% below this industry median. Based on the distribution chart, Australian Clinical Labs ranks #36 out of 105 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Australian Clinical Labs has a GF Score™ of 56/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Australian Clinical Labs' EV-to-EBIT compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Australian Clinical Labs ranks #36 out of 105 companies for EV-to-EBIT. This puts Australian Clinical Labs in the upper half of its industry. The industry median EV-to-EBIT is 23.47. Australian Clinical Labs' value of 16.37 is 30.3% below this benchmark. Historically, Australian Clinical Labs' own EV-to-EBIT has ranged from 3.20 to 25.01 over the past decade. While the company's 10-year median is 14.38 vs. the industry median of 23.47, Australian Clinical Labs has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Diagnostics & Research company?
The median EV-to-EBIT among Medical Diagnostics & Research companies is 23.47, based on 105 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Australian Clinical Labs's current EV-to-EBIT of 16.37 is 30.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Australian Clinical Labs and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-EBIT is 23.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Australian Clinical Labs's current EV-to-EBIT is 16.37, which is 14% above median its own 10-year median of 14.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Australian Clinical Labs stock overvalued right now?
Based on GuruFocus' analysis, Australian Clinical Labs (ASX:ACL) is currently considered Modestly Undervalued. The stock's GF Value™ is A$3.06, compared to a current price of A$2.38 — trading 22.2% below its estimated fair value. The current EV-to-EBIT is 16.37, which is 14% above median its 10-year median of 14.38 and 30.3% below the Medical Diagnostics & Research industry median of 23.47. Australian Clinical Labs' overall GF Score™ is 56/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Australian Clinical Labs (ASX:ACL), the current EV-to-EBIT is 16.37 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Australian Clinical Labs (ASX:ACL) Overvalued in 2026?
Based on GuruFocus' analysis, Australian Clinical Labs stock appears to be undervalued.
The current stock price of A$2.38 is trading 22.2% below its estimated GF Value™ of A$3.06.
GuruFocus considers Australian Clinical Labs to be Modestly Undervalued.
Key valuation signals for ASX:ACL:
EV-to-EBIT: 16.37 (14% above median its 10-year median of 14.38)
GF Value™: A$3.06 vs. price of A$2.38 (22.2% below fair value)
Industry Position: 30.3% below the Medical Diagnostics & Research median (#36 of 105)
No single metric tells the full story. See the ASX:ACL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Australian Clinical Labs is Australia's third-largest private pathology provider. ACL earns almost its entire group revenue from pathology services in Australia, which are mostly earned via the publicly funded health Medicare system. ACL is well established in the states of Western Australia, South Australia, Victoria, and the Northern Territory.
56GF Score
Get the complete analysis for ASX:ACL
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:ACL has been successfully added to your 
